SCHEMBL2053269

SCHEMBL2053269

CCOc1ccc(OCC)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.52
KDM1A O60341 2/20 0.51
FFAR1 O14842 5/20 0.49
PPARD Q03181 4/20 0.49
KDM4E B2RXH2 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TDP1 Q9NUW8 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
CACNA1C Q13936 1/20 0.44
TUBB1 Q9H4B7 1/20 0.44
TSHR P16473 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
KMT2A Q03164 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
EPHX1 P07099 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17357094 0.88 TUBB1 (0.49) NQO1KDM1AFFAR1PPARDKDM4E
SCHEMBL18361620 0.88 TUBB1 (0.53) NQO1FFAR1PPARDKDM4ECACNA1C
SCHEMBL1510002 0.87 KDM1A (0.45) NQO1KDM1AFFAR1PPARDKDM4E
SCHEMBL6349213 0.85 KDM1A (0.46) NQO1KDM1AFFAR1PPARDKDM4E
SCHEMBL177773 0.85 KDM1A (0.46) NQO1KDM1AFFAR1PPARDKDM4E
SCHEMBL1128493 0.83 FFAR1 (0.59) KDM1AFFAR1PPARD
SCHEMBL1547853 0.83 NQO1 (0.56) NQO1FFAR1TDP1CACNA1CTSHR
SCHEMBL11940790 0.82 KDM1A (0.44) NQO1KDM1AFFAR1PPARDKDM4E
SCHEMBL16855936 0.82 NQO1 (0.42) NQO1KDM1AFFAR1PPARDKDM4E
SCHEMBL6349214 0.82 KDM1A (0.44) NQO1KDM1AFFAR1PPARDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102241621-A 5,5-disubstituted-2-iminopyrrolidine derivatives, preparation method thereof, and medical applications thereof JIANGSU HENGRUI MEDICINE CO 2011-11-16 CN disclosed
WO-2011064789-A1 IMPROVED PROCESS FOR THE PREPARATION OF HALO-DIALKOXYBENZENES HIKAL LIMITED (IN) 2011-06-03 WO disclosed
US-7951305-B2 Compound having hydrocoumarin skeleton, liquid crystal composition, and liquid crystal display device CHISSO CORPORATION (JP) 2011-05-31 US disclosed
US-20090267026-A1 COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2009-10-29 US disclosed
EP-0922712-B1 Novel electron donor containing compositions UNION CARBIDE CHEM PLASTIC (US) 2002-12-18 EP disclosed
EP-0922712-A1 Novel electron donor containing compositions UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1999-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090267026-A1 COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE HCN2, PIEZO1, TRPV4 NQO1 2626/4885KDM1A 2972/4885FFAR1 3126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.